Skip to content
Clinical Trials – home
Therapeutic area

Infections and infestations

  • 681 clinical trials
  • 264 recruiting
  • 283 conditions
  • 27 countries

Conditions in this area

283 conditions with trials, the busiest first

Clinical trials in Infections and infestations

681 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

681 clinical trials

Mite allergy+1

Recruiting

Safety of a rush up‑dosing regimen of dust mite allergen extract versus conventional up‑dosing in adults with dust mite rhinitis/rhinoconjunctivitis with asthma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Phenol
  • Sponsor:HAL Allergy B.V.

A study comparing furazidin and clindamycin for women with bacterial vaginosis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Furazidine
  • Sponsor:Adamed Pharma S.A.

COVID-19

Recruiting

A study testing molnupiravir in adults with COVID-19 who are not hospitalized and are at high risk for serious illness

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Molnupiravir
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Absorption of Meropenem and Vaborbactam in Children with Complicated Urinary Tract Infections

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Meropenem
  • Sponsor:Menarini Ricerche S.p.A.

Title: Study of tianeptine effectiveness in treating cognitive symptoms (brain fog) in patients who have recovered from COVID-19

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tianeptine Sodium
  • Sponsor:Agencja Badań Medycznych

Oral herpes

Recruiting

Study comparing aciclovir gel and cream effectiveness in treating recurrent cold sores (herpes labialis)

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Laboratorios Ojer Pharma S.L.

A Study to Evaluate the Effectiveness and Safety of AHB‑137 in Adults with Chronic Hepatitis B Already Treated with Nucleos(t)ide Analogue Therapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Ausperbio Therapeutics Inc.

HIV infection

Recruiting

Durable HIV-1 control with 10-1074-LS, 3BNC117-LS and nivolumab in adults on ART: a randomized double‑blind placebo‑controlled trial

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Nivolumab
  • Sponsor:Region Midtjylland

Rabies

Recruiting

Rabies Prophylaxis in Healthy Volunteers After Rabies Virus (Inactivated) Strain Flury LEP Vaccination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Rabies virus (inactivated) strain Flury LEP
  • Sponsor:Institute Of Tropical Medicine

Short-course (7‑day) versus standard 14‑day ciprofloxacin treatment for men with serious urinary tract infection

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:Universitair Ziekenhuis Brussel

Early Stopping of Antibiotic Treatment in Children with Cancer and Febrile Neutropenia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Amikacin
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Study on the Effectiveness of Clarithromycin and Other Drug Combinations for Patients with Uncomplicated Staphylococcus aureus Blood Infection

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin
  • Sponsor:Hvidovre Hospital

Substances studied in this area

The therapies tested most often in Infections and infestations trials.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.